Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Institute Catalá Oncología
Barcelona, EspañaPublicacions en col·laboració amb investigadors/es de Institute Catalá Oncología (10)
2024
-
Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738
-
Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy
Clinical and Translational Oncology
2022
-
Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer
Journal for immunotherapy of cancer, Vol. 10, Núm. 12
2020
-
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Science Translational Medicine, Vol. 12, Núm. 565
2018
-
Radium-223 international early access program: Results from the Spanish subset
Future Oncology, Vol. 14, Núm. 1, pp. 41-50
2017
-
Intratumoral delivery of immunotherapy - Act locally, think globally
Journal of Immunology, Vol. 198, Núm. 1, pp. 31-39
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97
2013
-
Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC)
Clinical and Translational Oncology, Vol. 15, Núm. 9, pp. 698-704
2009
-
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
Annals of Oncology, Vol. 20, Núm. 11, pp. 1803-1812
2006
-
A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer
International Journal of Gynecological Cancer, Vol. 16, Núm. 1, pp. 71-76